Results of 90 Day Tenofovir plus Levonorgestrel Vaginal Ring Trial: The CONRAD 138 study
This article from PLOS One presents the results of a randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics, and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women to prevent both pregnancy and HIV.
How Might We Motivate Uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers
This article from Frontiers in Reproductive Health describes the results of a study to identify barriers and motivators for Dual Prevention Pill (DPP) uptake to inform the development of a DPP demand generation strategy and broader introduction efforts for Multipurpose Prevention Technologies.
Rapid Landscape Analysis of National Vertical Transmission Policies for Inclusion of PrEP for Pregnant and Breastfeeding People
Elimination of vertical transmission of HIV will require expanded access to HIV prevention strategies, such as PrEP, for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of HIV pre-exposure prophylaxis (PrEP) to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that…
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Report
This report was from the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and FP…
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Slides
These slides were featured at the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and…
Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative findings on MPT attribute preferences from the CUPID study (MTN-045)
This article from the Journal of the International AIDS Society uses data from the Microbicide Trials Network 045 study in Uganda and Zimbabwe to examine (1) how couples make decisions on existing non-Multipurpose Technology (MPT) HIV and pregnancy prevention products; (2) how couples make decisions on future ideal-MPT products; and (3) how these decision-making processes…
DPP Audience & Provider Insights for the DPP Research and Marketing Plan: Phase 1 Research Findings
This report, by M&C Saatchi World Services, AVAC, and partners, highlights learnings from Human-Centered Design Research undertaken in 2022 to understand the values and motivations of potential users and influencers of the Dual Prevention Pill (DPP) in Kenya, South Africa, and Zimbabwe.
Dual Prevention Pill Desk Review Insights
This desk review by M&C Saatchi collates existing data and insights related to uptake and adherence to HIV prevention, contraceptive, and multi-purpose technology pill products; confirms and identifies gaps in the existing knowledge base; and prompts discussions around key learning questions that need to be addressed to develop a robust and effective marketing and demand…
Review of Effective Marketing and Demand Creation Strategies in HIV Prevention and Family Planning that May Inform Demand-Side Thinking for the Dual Prevention Pill
This scoping review aims to document effective and sustainable demand creation strategies used in HIV prevention and Family Planning interventions, how they may be adapted for the Dual Prevention Pill (DPP), and explores what could be done differently for the DPP.
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through 2024.
The Future of ARV-Based Prevention and More
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.